Cogent Biosciences, Inc. (COGT) Research

Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.

Market snapshot

Symbol
COGT
Price
$34.54
Day change
+2.58%
Market cap
$5.9B
P/E ratio
-6.57x
52-week range
6.92-43.73
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$49.40

Recent news

  • Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts

    UBS analysts have outlined a set of high-conviction healthcare ideas where they believed the market was underappreciating earnings durability and the scale of upcoming catalysts, focusing on stocks backed by differentiated views and proprietary insights. In biotechnology, they identified Cogent Biosciences (NASDAQ:COGT) as their top pick, arguing the company offered scarcity value as a SMID-cap advancing two late-stage, potentially blockbuster assets.

Peer companies

  • Agios Pharmaceuticals, Inc. (AGIO)
  • Denali Therapeutics Inc. (DNLI)
  • 89bio, Inc. (ETNB)
  • Galapagos N.V. (GLPG)
  • ImmunityBio, Inc. (IBRX)
  • Liquidia Corporation (LQDA)
  • Ocular Therapeutix, Inc. (OCUL)
  • Arcus Biosciences, Inc. (RCUS)

Recent insider activity

  • Harwin Peter Evan — A-Award (17901 shares) on 2026-06-09
  • Ferrante Karen Jean — A-Award (17901 shares) on 2026-06-09
  • CAIN CHRISTOPHER W. — A-Award (17901 shares) on 2026-06-09
  • Shegog Todd — A-Award (17901 shares) on 2026-06-09
  • Morris Arlene — A-Award (17901 shares) on 2026-06-09

Open Cogent Biosciences, Inc. (COGT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.